KRAS突变非小细胞肺癌中活性RAS抑制的应答与耐受机制
该临床前研究评估了RAS(ON)多选择性三复合物抑制剂RMC-7977在KRASG12C突变非小细胞肺癌中的抗肿瘤活性,并解析应答与耐受机制。广谱可逆性RASGTP抑制在多种原发或获得性RASG12C抑制剂耐药小鼠模型中产生优越且差异化的抗肿瘤活性;单细胞转录组分析发现支持肿瘤细胞长期存活的再生性黏液转录程序,晚期患者中黏液组织学特征预示对索托拉西布或阿达格拉西布的应答不佳。
要点
- RMC-7977广谱可逆抑制RASGTP,在KRASG12C突变NSCLC耐药小鼠模型中显示优越抗肿瘤活性。
- 单细胞转录组建构体内图谱,发现再生性黏液转录程序支持肿瘤细胞长期存活。
- 晚期KRASG12C突变NSCLC中黏液组织学特征预示对索托拉西布或阿达格拉西布应答不佳。
核心结论
- 临床前RAS(ON)多选择性抑制剂RMC-7977对原发或获得性RASG12C抑制剂耐药的KRASG12C突变NSCLC难治亚群显示强效持久抗肿瘤活性。
- 研究识别出支持RAS抑制剂耐受的保守黏液转录状态。
- 晚期KRASG12C突变NSCLC患者中黏液组织学特征预示对索托拉西布或阿达格拉西布应答不佳。
研究设计与样本
- 临床前研究,在多种原发或获得性RASG12C(ON)或RASG12C(OFF)抑制剂耐药的KRASG12C突变NSCLC小鼠模型中评估RMC-7977抗肿瘤活性。
- 采用时间分辨单细胞转录响应分析,建立NSCLC生态系统中多模式急性和慢性RAS通路抑制的体内图谱。
- 在晚期KRASG12C突变NSCLC患者中分析黏液组织学特征与索托拉西布或阿达格拉西布应答的关系。
主要发现
- 广谱可逆性RASGTP抑制联合或不联合共价靶向活性RASG12C,在多种原发或获得性RASG12C(ON)或RASG12C(OFF)抑制剂耐药的KRASG12C突变NSCLC小鼠模型中产生优越且差异化的抗肿瘤活性。
- 时间分辨单细胞转录分析发现再生性黏液转录程序支持肿瘤细胞长期存活。
- 晚期KRASG12C突变NSCLC患者中,黏液组织学特征预示对索托拉西布或阿达格拉西布的应答不佳。
临床怎么用
- 作者认为研究结果对个体化医疗及开发以RAS抑制剂为锚点的合理治疗策略具有潜在意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resistance to inactive state-selective RASG12C inhibitors frequently entails accumulation of RASGTP, rendering effective inhibition of active RAS potentially desirable. Here, we evaluated the antitumor activity of the RAS(ON) multiselective tricomplex inhibitor RMC-7977 and dissected mechanisms of response and tolerance in KRASG12C-mutant non-small cell lung cancer (NSCLC). Broad-spectrum reversible RASGTP inhibition with or without concurrent covalent targeting of active RASG12C yielded superior and differentiated antitumor activity across diverse comutational KRASG12C-mutant NSCLC mouse models of primary or acquired RASG12C(ON) or RASG12C(OFF) inhibitor resistance. Interrogation of time-resolved single-cell transcriptional responses established an in vivo atlas of multimodal acute and chronic RAS pathway inhibition in the NSCLC ecosystem and uncovered a regenerative mucinous transcriptional program that supports long-term tumor cell persistence. In patients with advanced KRASG12C-mutant NSCLC, the presence of mucinous histologic features portended poor response to sotorasib or adagrasib. Our results have potential implications for personalized medicine and the development of rational RAS inhibitor-anchored therapeutic strategies. Significance: Our work reveals robust and durable antitumor activity of the preclinical RAS(ON) multiselective inhibitor RMC-7977 against difficult-to-treat subsets of KRASG12C-mutant NSCLC with primary or acquired RASG12C inhibitor resistance and identifies a conserved mucinous transcriptional state that supports RAS inhibitor tolerance. See related commentary by Marasco and Misale, p. 2018.
引用
- Araujo HA, Pechuan-Jorge X, Zhou T, et al. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2024. PMID: 38975897. doi:10.1158/2159-8290.CD-24-0421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。